2029 Biosimilars Marketing Vaccine 
Vial
MARCH 1, 2024
By geographical region, the global CRO services market in 2023 was dominated by North America. Growth factors for this market included the growing size of the pharmaceutical industry, the increasing number of clinical trials , substantial funds dedicated to pharma and biotech R&D, and the growing biosimilars and generics market.
FDA Law Blog: Biosimilars
DECEMBER 3, 2023
covered insulin product or vaccine). Each phase-in policy allows eligible manufacturers to build up in a stepwise manner to the 10% and 20% applicable discounts by 2029 and 2031, respectively. state pharmaceutical assistance programs). had Part D expenditures on or before August 16, 2022).
Expert insights. Personalized for you.
52 
Let's personalize your content